Verisante Technology Inc. (VRSEF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 1.10 means the share price is 1.10 times one year of earnings per share. Beta 4.22: the stock has moved about 322% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerVerisante Technology Inc. (VRSEF) trades at $0.002. Verisante Technology Inc. is a Canadian company formerly focused on designing and manufacturing cancer diagnostic devices. Currently, the company does not have significant operations. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for VRSEF: VRSEF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Verisante Technology Inc. (VRSEF) Healthcare & Pipeline Overview
Verisante Technology Inc., based in Canada, previously engaged in the design and manufacture of cancer diagnostic devices. Currently without significant operations, the company's future direction remains uncertain within the competitive medical devices sector, where innovation and market access are critical for success.
What Is the Investment Thesis for VRSEF?
Investing in Verisante Technology Inc. (VRSEF) presents significant risks due to the company's current lack of significant operations. The company's past involvement in cancer diagnostic devices offers a glimpse into its potential, but without active operations, revenue generation is non-existent. Any investment decision hinges on the company's ability to revitalize its operations and secure funding for future endeavors. Potential investors should closely monitor any announcements regarding strategic changes or new business initiatives. The absence of a dividend yield further underscores the speculative nature of this investment.
Based on FMP financials and quantitative analysis
VRSEF Key Highlights
Market capitalization of $0.00B indicates the company's minimal value and lack of investor confidence.
- A P/E ratio of -5.11 reflects the company's unprofitability and negative earnings.
- Beta of 4.22 suggests the stock is significantly more volatile than the market average.
- The company currently offers no dividend yield, providing no income for investors.
- The company 'does not have significant operations' indicating a pause or cessation of core business activities.
Who Are VRSEF's Competitors?
VRSEF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AEMD Aethlon Medical, Inc. | $4.84 | -5.28% | $8.21M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $2.38 | -0.21% | $36.2M | 39 5-pillar |
| LNSR LENSAR, Inc. | $4.85 | -1.22% | $59.6M | 44 5-pillar |
| HSDT Solana Company | $1.66 | +1.84% | $104M | 43 5-pillar |
| APYX Apyx Medical Corporation | $2.49 | -2.54% | $105M | 33 5-pillar |
| OWLT Owlet, Inc. | $3.67 | +12.92% | $110M | 41 5-pillar |
| INGN Inogen, Inc. | $5.42 | -2.69% | $141M | 37 5-pillar |
| ANIK Anika Therapeutics, Inc. | $13.28 | -2.50% | $178M | 71 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VRSEF's Key Strengths?
Previous experience in cancer diagnostic device development.
- Potential intellectual property assets.
- Established company infrastructure (if any remains).
What Are VRSEF's Weaknesses?
Lack of significant current operations.
- Limited financial resources.
- Uncertain future direction.
- Negative P/E ratio indicating unprofitability.
What Are the Key Risks for VRSEF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- The company's lack of significant operations poses a significant risk to investors.
- Intense competition in the medical device industry.
- Stringent regulatory requirements and potential delays in obtaining approvals.
- Technological obsolescence and the need for continuous innovation.
- Economic downturn affecting healthcare spending and demand for diagnostic devices.
What Are VRSEF's Competitive Advantages?
- Potential intellectual property related to cancer diagnostic technology (if any remains).
- Prior experience in the design and manufacturing of medical devices.
- Established brand recognition (if any remains) within the cancer diagnostics market.
What Does VRSEF Do?
Verisante Technology Inc. was incorporated in 2006 and later rebranded from T-Ray Science Inc. in January 2011. Headquartered in Vancouver, Canada, the company's historical focus was on the development and production of innovative cancer diagnostic devices. While the company aimed to provide advanced tools for early cancer detection, it currently does not have significant operations. The company's previous activities centered around leveraging technology for improved diagnostic accuracy and patient outcomes. However, the company's present state indicates a pause or shift in its business strategy. The company's history reflects an ambition to contribute to the medical device industry, specifically in the area of cancer diagnostics, but its current lack of operations suggests a need for strategic reevaluation or restructuring to regain its market presence and operational capabilities. The company's future direction remains uncertain.
What Products and Services Does VRSEF Offer?
- Formerly designed and manufactured cancer diagnostic devices.
- Aimed to provide innovative tools for early cancer detection.
- Sought to improve diagnostic accuracy and patient outcomes.
- Previously operated under the name T-Ray Science Inc.
- Currently does not have significant operations.
How Does VRSEF Make Money?
- Historically, the business model focused on developing and selling cancer diagnostic devices.
- Revenue generation was likely based on direct sales to hospitals, clinics, and research institutions.
- The company may have explored licensing agreements or partnerships for technology distribution.
What Industry Does VRSEF Operate In?
Verisante Technology Inc. operates within the medical devices industry, a sector characterized by rapid technological advancements and stringent regulatory requirements. The industry is highly competitive, with established players and emerging startups vying for market share. Companies in this sector must continuously innovate to meet evolving healthcare needs and maintain a competitive edge. Given Verisante's current lack of significant operations, it faces an uphill battle to re-enter the market and compete with established companies. The medical device industry is projected to grow, driven by an aging population and increasing demand for advanced diagnostic and treatment solutions.
Who Are VRSEF's Key Customers?
- Hospitals and medical centers requiring diagnostic equipment.
- Clinics specializing in cancer screening and diagnosis.
- Research institutions conducting cancer-related studies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Verisante Technology Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Thomas A. Braun. VRSEF has traded publicly since 2011.
Key Financial Metrics
VRSEF trades at a trailing price-to-earnings ratio of 1.10, below the Healthcare sector average of ~21.70x. Its free cash flow yield is -24.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.10 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 75.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Verisante Technology Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
VRSEF Latest News
-
Verisante: Q3 Earnings Snapshot
Yahoo! Finance: VRSEF News · Nov 11, 2026
VRSEF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VRSEF.
Price Targets
Wall Street price target analysis for VRSEF.
VRSEF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VRSEF; grades run from A+ (80-100) to F (below 30).
Leadership: Thomas A. Braun
CEO
Thomas A. Braun serves as the CEO of Verisante Technology Inc. His background likely includes experience in business management and potentially in the medical device or technology sectors. His leadership is crucial for guiding the company through its current challenges and potential restructuring efforts.
Track Record: Due to the company's current state of limited operations, it is difficult to assess Thomas A. Braun's recent track record. His previous achievements and strategic decisions at Verisante Technology Inc. are not detailed in the provided data. The company's future performance will be a key indicator of his leadership effectiveness.
VRSEF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Verisante Technology Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in VRSEF.
- Low trading volume and wide bid-ask spreads make it difficult to execute trades.
- The OTC Other tier is associated with higher risk of fraud and manipulation.
- The company's lack of significant operations raises concerns about its long-term viability.
- The high beta of 4.22 indicates extreme price volatility.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business plan and prospects for future growth.
- Evaluate the company's competitive position within the medical device industry.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before making any investment decisions.
- The company was incorporated in 2006, indicating a history of operations.
- The company was previously involved in the design and manufacture of cancer diagnostic devices.
- The company has a CEO (Thomas A. Braun) in place.
VRSEF Healthcare Stock FAQ
What are the main risks for VRSEF?
The main risks for Verisante Technology Inc. stem from its current lack of significant operations, which raises concerns about its long-term viability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's current state.